Liquidia Corporation (NASDAQ:LQDA) Receives $39.67 Consensus Target Price from Brokerages

Shares of Liquidia Corporation (NASDAQ:LQDA) have been assigned an average recommendation of “Moderate Buy” from the eleven analysts that are covering the firm, MarketBeat reports. Two equities research analysts have rated the stock with a sell recommendation, seven have assigned a buy recommendation and two have given a strong buy recommendation to the company. The average 1 year target price among analysts that have covered the stock in the last year is $39.6667.

LQDA has been the subject of a number of analyst reports. HC Wainwright raised their price objective on Liquidia from $35.00 to $50.00 and gave the stock a “buy” rating in a research report on Tuesday, November 4th. Zacks Research raised shares of Liquidia from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, January 13th. Jefferies Financial Group raised their price target on shares of Liquidia from $45.00 to $55.00 and gave the stock a “buy” rating in a report on Tuesday, January 13th. Needham & Company LLC upped their price objective on shares of Liquidia from $36.00 to $52.00 and gave the company a “buy” rating in a research note on Tuesday, November 4th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Liquidia in a research note on Thursday, January 22nd.

Insider Activity

In other Liquidia news, insider Rajeev Saggar sold 21,142 shares of Liquidia stock in a transaction that occurred on Monday, January 12th. The stock was sold at an average price of $37.43, for a total value of $791,345.06. Following the completion of the sale, the insider directly owned 176,883 shares in the company, valued at approximately $6,620,730.69. The trade was a 10.68% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CAO Dana Boyle sold 1,580 shares of the business’s stock in a transaction that occurred on Monday, January 26th. The shares were sold at an average price of $41.65, for a total value of $65,807.00. Following the completion of the transaction, the chief accounting officer directly owned 178,848 shares in the company, valued at approximately $7,449,019.20. This trade represents a 0.88% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 216,820 shares of company stock worth $8,102,685. 30.10% of the stock is owned by insiders.

Institutional Trading of Liquidia

Several large investors have recently modified their holdings of the stock. Federated Hermes Inc. bought a new stake in Liquidia in the 3rd quarter valued at about $7,290,000. Caprock Group LLC bought a new position in Liquidia in the third quarter worth approximately $37,114,000. Campbell & CO Investment Adviser LLC acquired a new stake in Liquidia in the third quarter valued at approximately $2,026,000. XTX Topco Ltd bought a new stake in shares of Liquidia during the second quarter valued at approximately $1,485,000. Finally, Tyro Capital Management LLC bought a new stake in shares of Liquidia during the second quarter valued at approximately $15,473,000. Institutional investors and hedge funds own 64.54% of the company’s stock.

Liquidia Stock Performance

NASDAQ LQDA opened at $33.84 on Friday. The company has a market capitalization of $2.94 billion, a price-to-earnings ratio of -23.50, a PEG ratio of 1.07 and a beta of 0.46. The company has a quick ratio of 1.96, a current ratio of 2.20 and a debt-to-equity ratio of 6.19. Liquidia has a twelve month low of $11.26 and a twelve month high of $46.67. The stock has a fifty day simple moving average of $37.46 and a 200 day simple moving average of $30.06.

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).